Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Effectiveness and Safety of Lacosamide, A Third-generation Anti-seizure Medication, for Poststroke Seizure and Epilepsy: A Literature Review

Author(s): Yu-Shiue Chen, Ming-Chi Lai, Tsang-Shan Chen, Yung-Hsin Tseng, Ya Jhen Li and Chin-Wei Huang*

Volume 21, Issue 10, 2023

Published on: 20 June, 2023

Page: [2126 - 2133] Pages: 8

DOI: 10.2174/1570159X21666230616114255

Price: $65

conference banner
Abstract

Advances in stroke treatment have resulted in a dramatic reduction in stroke mortality. Nevertheless, poststroke seizures and epilepsy are issues of clinical importance affecting survivors. Additionally, stroke is the most common cause of epilepsy in older adults. Although numerous antiseizure medications exist, studies are needed to provide robust evidence of the efficacy and tolerability of these medicines for treating poststroke seizures and epilepsy. Crucially, the newer generations of antiseizure medications require testing. Lacosamide, a third-generation antiseizure medication approved for treating localization-related epilepsy, has a novel mechanism of selectively enhancing the slow inactivation of sodium channels. This literature review evaluated whether lacosamide is effective and safe for the treatment of poststroke seizures and epilepsy. This review critically analyzed studies published in major academic databases (Pubmed, Embase, and Cochrane Library) from inception through June 2022 regarding the interaction of lacosamide with poststroke seizures and epilepsy. We included clinical prospective, retrospective, and case studies on patients with poststroke seizure and epilepsy, lacosamide as a treatment for seizures, neuroprotection in animal models of seizures, and the safety of lacosamide when coadministering anticoagulants. Clinical studies revealed lacosamide to be an effective antiseizure medication with high efficacy and tolerability in patients with poststroke seizures and epilepsy. In animal models, lacosamide proved effective at seizure reduction and neuroprotection. Pharmacokinetic studies demonstrated the safety of lacosamide when coadministering conventional and new anticoagulants. The literature suggests that Lacosamide is a promising candidate antiseizure medication for patients with poststroke seizures and epilepsy.

Keywords: Lacosamide, poststroke, seizure, epilepsy, anti-seizure medication, effectiveness, safety.

« Previous Next »
[1]
Myint, P.K.; Staufenberg, E.F.A.; Sabanathan, K. Post-stroke seizure and post-stroke epilepsy. Postgrad. Med. J., 2006, 82(971), 568-572.
[http://dx.doi.org/10.1136/pgmj.2005.041426] [PMID: 16954451]
[2]
Huang, C.W.; Saposnik, G.; Fang, J.; Steven, D.A.; Burneo, J.G. Influence of seizures on stroke outcomes: A large multicenter study. Neurology, 2014, 82(9), 768-776.
[http://dx.doi.org/10.1212/WNL.0000000000000166] [PMID: 24489133]
[3]
Hsieh, C.Y.; Su, C.C.; Lai, E.C.C.; Chen, Y.S.; Huang, T.H.; Kao Yang, Y.H.; Chen, C.H.; Sung, S.F.; Huang, C.W. Risk of incident epilepsy after a middle cerebral artery territory infarction. Front. Neurol., 2022, 13, 765969.
[http://dx.doi.org/10.3389/fneur.2022.765969] [PMID: 35309553]
[4]
Tanaka, T.; Ihara, M. Post-stroke epilepsy. Neurochem. Int., 2017, 107, 219-228.
[http://dx.doi.org/10.1016/j.neuint.2017.02.002] [PMID: 28202284]
[5]
Zelano, J.; Redfors, P.; Åsberg, S.; Kumlien, E. Association between poststroke epilepsy and death: A nationwide cohort study. Eur. Stroke J., 2016, 1(4), 272-278.
[http://dx.doi.org/10.1177/2396987316669000] [PMID: 31008288]
[6]
Bryndziar, T.; Sedova, P.; Kramer, N.M.; Mandrekar, J.; Mikulik, R.; Brown, R.D., Jr; Klaas, J.P. Seizures following ischemic stroke: Frequency of occurrence and impact on outcome in a long-term population-based study. J. Stroke Cerebrovasc. Dis., 2016, 25(1), 150-156.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2015.09.008] [PMID: 26454641]
[7]
Ferlazzo, E.; Gasparini, S.; Beghi, E.; Sueri, C.; Russo, E.; Leo, A.; Labate, A.; Gambardella, A.; Belcastro, V.; Striano, P.; Paciaroni, M.; Pisani, L.R.; Aguglia, U. Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta-analysis of risk factors. Epilepsia, 2016, 57(8), 1205-1214.
[http://dx.doi.org/10.1111/epi.13448] [PMID: 27381481]
[8]
Feher, G.; Gurdan, Z.; Gombos, K.; Koltai, K.; Pusch, G.; Tibold, A.; Szapary, L. Early seizures after ischemic stroke: Focus on thrombolysis. CNS Spectr., 2020, 25(1), 101-113.
[http://dx.doi.org/10.1017/S1092852919000804] [PMID: 30915936]
[9]
Hesdorffer, D.C.; Benn, E.K.T.; Cascino, G.D.; Hauser, W.A. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia, 2009, 50(5), 1102-1108.
[http://dx.doi.org/10.1111/j.1528-1167.2008.01945.x] [PMID: 19374657]
[10]
Becker, D.A.; Long, L.; Santilli, N.; Babrowicz, J.; Peck, E.Y. Patient, caregiver, and healthcare professional perspectives on seizure control and treatment goals. Epilepsy Behav., 2021, 117, 107816.
[http://dx.doi.org/10.1016/j.yebeh.2021.107816] [PMID: 33626491]
[11]
Holtkamp, M.; Beghi, E.; Benninger, F.; Kälviäinen, R.; Rocamora, R.; Christensen, H. European Stroke Organisation guidelines for the management of post-stroke seizures and epilepsy. Eur. Stroke J., 2017, 2(2), 103-115.
[http://dx.doi.org/10.1177/2396987317705536] [PMID: 31008306]
[12]
Huang, Y.H.; Chi, N.F.; Kuan, Y.C.; Chan, L.; Hu, C.J.; Chiou, H.Y.; Chien, L.N. Efficacy of phenytoin, valproic acid, carbamazepine and new antiepileptic drugs on control of late-onset post-stroke epilepsy in Taiwan. Eur. J. Neurol., 2015, 22(11), 1459-1468.
[http://dx.doi.org/10.1111/ene.12766] [PMID: 26148132]
[13]
Hsu, C.Y.; Cheng, C.Y.; Lee, J.D.; Lee, M.; Ovbiagele, B. Effects of long-term antiepileptic drug monotherapy on all-cause death in patients with post-stroke epilepsy: A nationwide population-based study. BMC Neurol., 2021, 21(1), 226.
[http://dx.doi.org/10.1186/s12883-021-02241-5] [PMID: 34154568]
[14]
Brigo, F.; Lattanzi, S.; Zelano, J.; Bragazzi, N.L.; Belcastro, V.; Nardone, R.; Trinka, E. Randomized controlled trials of antiepileptic drugs for the treatment of post-stroke seizures: A systematic review with network meta-analysis. Seizure, 2018, 61, 57-62.
[http://dx.doi.org/10.1016/j.seizure.2018.08.001] [PMID: 30096625]
[15]
Doty, P.; Rudd, G.D.; Stoehr, T.; Thomas, D. Lacosamide. Neurotherapeutics, 2007, 4(1), 145-148.
[http://dx.doi.org/10.1016/j.nurt.2006.10.002] [PMID: 17199030]
[16]
Strzelczyk, A.; Zöllner, J.P.; Willems, L.M.; Jost, J.; Paule, E.; Schubert-Bast, S.; Rosenow, F.; Bauer, S. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia, 2017, 58(6), 933-950.
[http://dx.doi.org/10.1111/epi.13716] [PMID: 28295226]
[17]
Brodie, M.J. Sodium channel blockers in the treatment of epilepsy. CNS Drugs, 2017, 31(7), 527-534.
[http://dx.doi.org/10.1007/s40263-017-0441-0] [PMID: 28523600]
[18]
Huang, C.W.; Hung, T.Y.; Wu, S.N. The inhibitory actions by lacosamide, a functionalized amino acid, on voltage-gated Na+ currents. Neuroscience, 2015, 287, 125-136.
[http://dx.doi.org/10.1016/j.neuroscience.2014.12.026] [PMID: 25534720]
[19]
Harris, J.A.; Murphy, J.A. Lacosamide and epilepsy. CNS Neurosci. Ther., 2011, 17(6), 678-682.
[http://dx.doi.org/10.1111/j.1755-5949.2010.00198.x] [PMID: 20950330]
[20]
Hoy, S.M. Lacosamide: A review in focal-onset seizures in patients with epilepsy. CNS Drugs, 2018, 32(5), 473-484.
[http://dx.doi.org/10.1007/s40263-018-0523-7] [PMID: 29785508]
[21]
Huang, C.W.W.; Brown, S.; Pillay, N.; Campo, M.D.; Tellez-Zenteno, J.; McLachlan, R.S. Electroencephalographic and electrocardiographic effect of intravenous lacosamide in refractory focal epilepsy. J. Clin. Neurophysiol., 2018, 35(5), 365-369.
[http://dx.doi.org/10.1097/WNP.0000000000000479] [PMID: 29851686]
[22]
Guilhoto, L.M.F.F.; Loddenkemper, T.; Gooty, V.D.; Rotenberg, A.; Takeoka, M.; Duffy, F.H.; Coulter, D.; Urion, D.; Bourgeois, B.F.; Kothare, S.V. Experience with lacosamide in a series of children with drug-resistant focal epilepsy. Pediatr. Neurol., 2011, 44(6), 414-419.
[http://dx.doi.org/10.1016/j.pediatrneurol.2010.12.003] [PMID: 21555051]
[23]
Rosenow, F.; Brandt, C.; Bozorg, A.; Dimova, S.; Steiniger-Brach, B.; Zhang, Y.; Ferrò, B.; Holmes, G.L.; Kälviäinen, R. Lacosamide in patients with epilepsy of cerebrovascular etiology. Acta Neurol. Scand., 2020, 141(6), 473-482.
[http://dx.doi.org/10.1111/ane.13230] [PMID: 32068241]
[24]
Sharma, A.; Singh, P.; Goyal, M.K.; Lal, V. Efficacy of intravenous lacosamide in refractory status epilepticus patients. Journal of Advanced Medical and Dental Sciences Research, 2019, 7(5), 131-135.
[25]
Belcastro, V.; Vidale, S.; Pierguidi, L.; Sironi, L.; Tancredi, L.; Striano, P.; Taborelli, A.; Arnaboldi, M. Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: A proof-of-concept, observational study. Seizure, 2013, 22(10), 905-907.
[http://dx.doi.org/10.1016/j.seizure.2013.07.011] [PMID: 23953988]
[26]
Mnatsakanyan, L.; Chung, J.M.; Tsimerinov, E.I.; Eliashiv, D.S. Intravenous Lacosamide in refractory nonconvulsive status epilepticus. Seizure, 2012, 21(3), 198-201.
[http://dx.doi.org/10.1016/j.seizure.2011.12.008] [PMID: 22244046]
[27]
Ylikotila, P.; Ketola, R.A.; Timonen, S.; Malm, H.; Ruuskanen, J.O. Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. Reprod. Toxicol., 2015, 57, 204-206.
[http://dx.doi.org/10.1016/j.reprotox.2015.07.068] [PMID: 26187779]
[28]
Mazzocchetti, P.; Tantucci, M.; Bastioli, G.; Calabrese, V.; Di Filippo, M.; Tozzi, A.; Calabresi, P.; Costa, C. Lacosamide protects striatal and hippocampal neurons from in vitro ischemia without altering physiological synaptic plasticity. Neuropharmacology, 2018, 135, 424-430.
[http://dx.doi.org/10.1016/j.neuropharm.2018.03.040] [PMID: 29614316]
[29]
Ahn, J.Y.; Yan, B.C.; Park, J.H.; Ahn, J.H.; Lee, D.H.; Kim, I.H.; Cho, J.H.; Chen, B.H.; Lee, J.C.; Cho, Y.S.; Shin, M.C.; Cho, J.H.; Hong, S.; Won, M.H.; Kim, S.K. Novel antiepileptic drug lacosamide exerts neuroprotective effects by decreasing glial activation in the hippocampus of a gerbil model of ischemic stroke. Exp. Ther. Med., 2015, 10(6), 2007-2014.
[http://dx.doi.org/10.3892/etm.2015.2794] [PMID: 26668588]
[30]
Stockis, A.; van Lier, J.J.; Cawello, W.; Kumke, T.; Eckhardt, K. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin. Epilepsia, 2013, 54(7), 1161-1166.
[http://dx.doi.org/10.1111/epi.12192] [PMID: 23614393]
[31]
Lip, G.Y.H.; Lane, D.A. Stroke prevention in atrial fibrillation: A systematic review. JAMA, 2015, 313(19), 1950-1962.
[http://dx.doi.org/10.1001/jama.2015.4369] [PMID: 25988464]
[32]
Gelosa, P.; Castiglioni, L.; Tenconi, M.; Baldessin, L.; Racagni, G.; Corsini, A.; Bellosta, S. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol. Res., 2018, 135, 60-79.
[http://dx.doi.org/10.1016/j.phrs.2018.07.016] [PMID: 30040996]
[33]
Stöllberger, C.; Finsterer, J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res., 2016, 126, 98-101.
[http://dx.doi.org/10.1016/j.eplepsyres.2016.06.003] [PMID: 27450623]
[34]
Steffel, J.; Verhamme, P.; Potpara, T.S.; Albaladejo, P.; Antz, M.; Desteghe, L.; Haeusler, K.G.; Oldgren, J.; Reinecke, H.; Roldan-Schilling, V.; Rowell, N.; Sinnaeve, P.; Collins, R.; Camm, A.J.; Heidbüchel, H.; Lip, G.Y.H.; Weitz, J.; Fauchier, L.; Lane, D.; Boriani, G.; Goette, A.; Keegan, R.; MacFadyen, R.; Chiang, C-E.; Joung, B.; Shimizu, W. The 2018 european heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur. Heart J., 2018, 39(16), 1330-1393.
[http://dx.doi.org/10.1093/eurheartj/ehy136] [PMID: 29562325]
[35]
Galgani, A.; Palleria, C.; Iannone, L.F.; De Sarro, G.; Giorgi, F.S.; Maschio, M.; Russo, E. Pharmacokinetic interactions of clinical interest between direct oral anticoagulants and antiepileptic drugs. Front. Neurol., 2018, 9, 1067.
[http://dx.doi.org/10.3389/fneur.2018.01067] [PMID: 30581412]
[36]
Testa, S.; Paoletti, O.; Legnani, C.; Dellanoce, C.; Antonucci, E.; Cosmi, B.; Pengo, V.; Poli, D.; Morandini, R.; Testa, R.; Tripodi, A.; Palareti, G. Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants. J. Thromb. Haemost., 2018, 16(5), 842-848.
[http://dx.doi.org/10.1111/jth.14001] [PMID: 29532628]
[37]
Wang, C.L.; Wu, V.C.C.; Chang, K.H.; Tu, H.T.; Kuo, C.F.; Huang, Y.T.; Chu, P.H.; Kuo, C.C.; Chang, S.H. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs. Eur. Heart J. Cardiovasc. Pharmacother., 2020, 6(3), 147-154.
[http://dx.doi.org/10.1093/ehjcvp/pvz035] [PMID: 31384926]
[38]
Paciullo, F.; Costa, C.; Gresele, P. Rivaroxaban plasma levels and levetiracetam: A case report. Ann. Intern. Med., 2020, 173(1), 71-72.
[http://dx.doi.org/10.7326/L19-0712] [PMID: 32283551]
[39]
Zaccara, G.; Perucca, E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord., 2014, 16(4), 409-431.
[http://dx.doi.org/10.1684/epd.2014.0714] [PMID: 25515681]
[40]
Corbellini, Á.B.; Torre, P.P.; Hristova, V.N.; Sanz, B.Z.; García, A.C.C.; Jorge, F.R.; García, J.L.C.; Díaz, P.P.; Catevilla, F.J.B. Cardioembolic acute cerebral micro-infarcts in the context of atrial fibrillation after low-dose intravenous infusion of lacosamide. Epileptic Disord., 2020, 22(1), 83-89.
[PMID: 32043469]
[41]
Chinnasami, S.; Rathore, C.; Duncan, J.S. Sinus node dysfunction: An adverse effect of lacosamide. Epilepsia, 2013, 54(6), e90-e93.
[http://dx.doi.org/10.1111/epi.12108] [PMID: 23360388]
[42]
Delaunois, A.; Colomar, A.; Depelchin, B.O.; Cornet, M. Cardiac safety of lacosamide: The non-clinical perspective. Acta Neurol. Scand., 2015, 132(5), 337-345.
[http://dx.doi.org/10.1111/ane.12413] [PMID: 25903789]
[43]
McLaughlin, K.; Carabetta, S.; Hunt, N.; Schuler, B.R.; Ting, C.; Tran, L.K.; Szumita, P.M.; Anger, K.E. Safety of intravenous push lacosamide compared with intravenous piggyback at a tertiary academic medical center. Ann. Pharmacother., 2021, 55(2), 181-186.
[http://dx.doi.org/10.1177/1060028020943569] [PMID: 32686466]

Rights & Permissions Print Cite
Article Metrics
56
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy